Literature DB >> 7470200

Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis.

P J Nestel, T Billington.   

Abstract

The possible mechanisms of action of probucol on the metabolism of low density lipoprotein and of high density lipoprotein were studied in 5 hyperlipidaemic subjects. The kinetics of LDL-B protein and of HDL-AI protein were determined by 2-pool analysis of specific radioactivity-time curves after reinjection of 131I-labelled LDL and 125I-labelled HDL at the end of placebo and treatment periods. Probucol increased the fractional removal rate of LDL in 4, an action probably linked to increased bile acid excretion which occurred in all 5 subjects. Nevertheless, the plasma cholesterol concentration fell significantly in only 3. The synthesis of HDL-AI protein fell substantially and was probably responsible for the consistent reduction in plasma apo-AI levels. Thus, probucol appears to enhance LDL-B protein removal and bile acid excretion but inhibits AI protein formation; all these effects may be determined in the small intestine.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7470200     DOI: 10.1016/0021-9150(81)90117-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  12 in total

1.  Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice.

Authors:  S H Zhang; R L Reddick; E Avdievich; L K Surles; R G Jones; J B Reynolds; S H Quarfordt; N Maeda
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

2.  Probucol inhibits oxidative modification of low density lipoprotein.

Authors:  S Parthasarathy; S G Young; J L Witztum; R C Pittman; D Steinberg
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

3.  The effect of probucol on the proliferation of cultured human umbilical vascular endothelial cells.

Authors:  T Tajika; Y Ono; K Ono; M Miura; Y Kyo
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-05       Impact factor: 2.416

Review 4.  Managing elevated blood lipid concentrations. Who, when and how?

Authors:  A M Dart
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

5.  Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia.

Authors:  D D Sugrue; I Trayner; G R Thompson; V J Vere; J Dimeson; Y Stirling; T W Meade
Journal:  Br Heart J       Date:  1985-03

Review 6.  Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.

Authors:  M M Buckley; K L Goa; A H Price; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

7.  Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.

Authors:  K Saku; B Zhang; K Hirata; Y Okura; H Bai; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

Authors:  F Heller; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  Lipid-lowering drugs. An overview of indications and optimum therapeutic use.

Authors:  D R Illingworth
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

10.  High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.

Authors:  K Saku; B Zhang; S Jimi; H Bai; K Hirata; N Sasaki; R Liu; K Arakawa
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.